Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Herstellerkennzeichnung
Die Herstellerinformationen sind derzeit nicht verfügbar.
Inhaltsangabe
Classification and Cytopathology of Myelodysplastic Syndromes.- The Classification of Myelodysplastic Syndromes.- Discussion.- Classification of Myelodysplastic Syndromes in Clinical Practice: Frequency of Subtypes.- Pathogenesis of Anaemia in the Myelodysplastic Syndrome.- Immunological Abnormalities in the Myelodysplastic Syndrome.- Pediatric Experiences in Myelodysplastic Syndrome.- Myelodysplastic Syndromes in Childhood: Description of 11 Cases.- The Value of Cytochemical Investigations in the Diagnosis of the Myelodysplastic Syndromes.- Enzyme Cytochemical Studies in Myelodysplastic Syndromes.- Immunological Phenotyping of Blood and Bone Marrow Cells From Patients with Myelodysplastic Syndromes.- Bone Marrow Biopsy in RAEB and RAEB-t Myelodysplastic Syndromes.- Discussion of Poster Session I.- Cyto- and Histopathology of Myelodysplastic Syndrome.- Maturation Pattern and Evolution of Leukemia in the Myelodysplastic Syndrome.- Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia.- The Prognostic Value of Abnormal Localization of Immature Precursors in the Myelodysplastic Syndromes.- Bone Marrow Histology in Myelodysplastic Syndromes: An Update.- Evolution of Myelodysplastic Syndromes.- Conversion of Myelodysplastic Subtypes to Acute Leukemia: A Follow-Up Study.- Primary Myelodysplastic Syndromes and Chronic Myelofibrosis.- Myelodysplastic Syndrome with Myelofibrosis: A Report of Seven Cases.- Chronic Myelomonocytic Leukemia.- Chronic Myelomonocytic Leukaemia and Atypical Chronic Myeloid Leukaemia.- Chronic Myelomonocytic Leukemia with Lymphadenopathy.- Generalized Lymphadenopathy in Juvenile Chronic Myelomonocytic Leukemia Is Due to Lymph Node Infiltration with Myelomonocytic Cells and Immature T Cells.- Impaired Monocyte/Macrophage Differentiation inthe Myelodysplastic Syndromes.- Discussion of Poster Session II.- Cytogenetic Anomalies and Molecular Biology of Myelodysplastic Syndromes.- Myelodysplastic Syndromes: Cytogenetic Anomalies and Their Clinical Significance.- Genetic Consequences of Chromosomal Abnormalities in the Myelodysplastic Syndromes.- ras Mutations in the Myelodysplastic Syndromes.- Study of the Rearrangement of Proto-oncogene MET in 88 Cases of Myelodysplastic Syndromes.- In Vitro-Culture Studies in Myelodysplastic Syndromes.- ras Oncogenes in Myelodysplastic Syndromes.- Growth Factors in Myelodysplastic Syndromes.- In Vitro Granulopoiesis in Myelodysplastic Syndromes According to the FAB Classification.- Therapy of Myelodysplastic Syndromes: Supportive Care and Chemotherapy.- Therapeutic Implications of Understanding Pathogenesis: Clinical Relevance of Prognostic Factors.- Supportive Therapy and Bone Marrow Transplantation in MDS.- Retinoic Acid Therapy in the Myelodysplastic Syndrome.- Phase III Evaluation of Low-Dose Cytosine Arabinoside Versus Supportive Care in the Treatment of Adults With Myelodysplastic Syndrome: An Intergroup Study by the Eastern Cooperative Oncology Group and the Southwest Oncology Group - Preliminary Results.- Intensive Chemotherapy in Myelodysplastic Syndromes.- Therapeutic Effects of Low-Dose Cytosine Arabinoside Without or With 1;25-Dihydroxyvitamin D3 in Myelodysplastic Syndromes and in Elderly Acute Nonlymphocytic Leukemia.- Low-Dose Cytosine Arabinoside Regimen Adapted to the FAB Classifications of Myelodysplastic Syndromes: Is it Superior to Uniform Treatment for all Types of MDS?.- Results of Low-Dose Cytosine Arabinoside and Agressive Chemotherapy in Patients with Advanced Myelodysplastic Syndromes.- Aggressive Chemotherapy in Adult Primary MyelodysplasticSyndromes: A Report on 29 Cases.- Therapy of Myelodysplastic Syndromes: Biological Response Modifiers and Growth Factors.- Recombitant ?2b-Interferon in the Management of Myelodysplastic Syndromes.- A Phase II Clinical Trial of Recombinant Interferon-? on Myelodysplastic Syndromes.- Treatment of Patients with Myelodysplastic Syndromes with Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor: A Phase I/II Trial.- Combined Treatment Modality with Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor and Low-Dose Cytosine Arabinoside in Patients with Myelodysplastic Syndromes.- GM-CSF Combined with Low-Dose Cytosine Arabinoside: A Trial Proposed for High-Risk Myelodysplastic Syndromes and Results of a Dose-Finding Study.- Discussion of Poster Session III.
Classification and Cytopathology of Myelodysplastic Syndromes.- The Classification of Myelodysplastic Syndromes.- Discussion.- Classification of Myelodysplastic Syndromes in Clinical Practice: Frequency of Subtypes.- Pathogenesis of Anaemia in the Myelodysplastic Syndrome.- Immunological Abnormalities in the Myelodysplastic Syndrome.- Pediatric Experiences in Myelodysplastic Syndrome.- Myelodysplastic Syndromes in Childhood: Description of 11 Cases.- The Value of Cytochemical Investigations in the Diagnosis of the Myelodysplastic Syndromes.- Enzyme Cytochemical Studies in Myelodysplastic Syndromes.- Immunological Phenotyping of Blood and Bone Marrow Cells From Patients with Myelodysplastic Syndromes.- Bone Marrow Biopsy in RAEB and RAEB-t Myelodysplastic Syndromes.- Discussion of Poster Session I.- Cyto- and Histopathology of Myelodysplastic Syndrome.- Maturation Pattern and Evolution of Leukemia in the Myelodysplastic Syndrome.- Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia.- The Prognostic Value of Abnormal Localization of Immature Precursors in the Myelodysplastic Syndromes.- Bone Marrow Histology in Myelodysplastic Syndromes: An Update.- Evolution of Myelodysplastic Syndromes.- Conversion of Myelodysplastic Subtypes to Acute Leukemia: A Follow-Up Study.- Primary Myelodysplastic Syndromes and Chronic Myelofibrosis.- Myelodysplastic Syndrome with Myelofibrosis: A Report of Seven Cases.- Chronic Myelomonocytic Leukemia.- Chronic Myelomonocytic Leukaemia and Atypical Chronic Myeloid Leukaemia.- Chronic Myelomonocytic Leukemia with Lymphadenopathy.- Generalized Lymphadenopathy in Juvenile Chronic Myelomonocytic Leukemia Is Due to Lymph Node Infiltration with Myelomonocytic Cells and Immature T Cells.- Impaired Monocyte/Macrophage Differentiation inthe Myelodysplastic Syndromes.- Discussion of Poster Session II.- Cytogenetic Anomalies and Molecular Biology of Myelodysplastic Syndromes.- Myelodysplastic Syndromes: Cytogenetic Anomalies and Their Clinical Significance.- Genetic Consequences of Chromosomal Abnormalities in the Myelodysplastic Syndromes.- ras Mutations in the Myelodysplastic Syndromes.- Study of the Rearrangement of Proto-oncogene MET in 88 Cases of Myelodysplastic Syndromes.- In Vitro-Culture Studies in Myelodysplastic Syndromes.- ras Oncogenes in Myelodysplastic Syndromes.- Growth Factors in Myelodysplastic Syndromes.- In Vitro Granulopoiesis in Myelodysplastic Syndromes According to the FAB Classification.- Therapy of Myelodysplastic Syndromes: Supportive Care and Chemotherapy.- Therapeutic Implications of Understanding Pathogenesis: Clinical Relevance of Prognostic Factors.- Supportive Therapy and Bone Marrow Transplantation in MDS.- Retinoic Acid Therapy in the Myelodysplastic Syndrome.- Phase III Evaluation of Low-Dose Cytosine Arabinoside Versus Supportive Care in the Treatment of Adults With Myelodysplastic Syndrome: An Intergroup Study by the Eastern Cooperative Oncology Group and the Southwest Oncology Group - Preliminary Results.- Intensive Chemotherapy in Myelodysplastic Syndromes.- Therapeutic Effects of Low-Dose Cytosine Arabinoside Without or With 1;25-Dihydroxyvitamin D3 in Myelodysplastic Syndromes and in Elderly Acute Nonlymphocytic Leukemia.- Low-Dose Cytosine Arabinoside Regimen Adapted to the FAB Classifications of Myelodysplastic Syndromes: Is it Superior to Uniform Treatment for all Types of MDS?.- Results of Low-Dose Cytosine Arabinoside and Agressive Chemotherapy in Patients with Advanced Myelodysplastic Syndromes.- Aggressive Chemotherapy in Adult Primary MyelodysplasticSyndromes: A Report on 29 Cases.- Therapy of Myelodysplastic Syndromes: Biological Response Modifiers and Growth Factors.- Recombitant ?2b-Interferon in the Management of Myelodysplastic Syndromes.- A Phase II Clinical Trial of Recombinant Interferon-? on Myelodysplastic Syndromes.- Treatment of Patients with Myelodysplastic Syndromes with Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor: A Phase I/II Trial.- Combined Treatment Modality with Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor and Low-Dose Cytosine Arabinoside in Patients with Myelodysplastic Syndromes.- GM-CSF Combined with Low-Dose Cytosine Arabinoside: A Trial Proposed for High-Risk Myelodysplastic Syndromes and Results of a Dose-Finding Study.- Discussion of Poster Session III.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
